G vs. MRK

Last updated Apr 1, 2026

Compare and contrast key facts about Genpact Limited (G) and Merck & Co., Inc. (MRK).

Performance

G vs. MRK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Genpact Limited (G) and Merck & Co., Inc. (MRK). The values are adjusted to include any dividend payments, if applicable.

G vs. MRK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
G Genpact Limited	-19.98%	10.56%	25.78%	-23.98%	-11.74%	29.51%	-0.93%	57.66%	-14.12%	31.54%
MRK Merck & Co., Inc.	15.13%	9.79%	-6.26%	1.01%	49.42%	1.75%	-7.20%	22.27%	39.95%	-1.49%

Fundamentals

Market Cap G : $6.52B MRK : $299.28B
EPS G : $3.14 MRK : $7.30
PE Ratio G : 11.87 MRK : 16.47
PEG Ratio G : 0.67 MRK : 0.01
PS Ratio G : 1.29 MRK : 4.63
PB Ratio G : 2.56 MRK : 5.77
Total Revenue (TTM) G : $5.08B MRK : $65.01B
Gross Profit (TTM) G : $1.83B MRK : $52.98B
EBITDA (TTM) G : $855.28M MRK : $28.80B

Returns By Period

In the year-to-date period, G achieves a -19.98% return, which is significantly lower than MRK's 15.13% return. Over the past 10 years, G has underperformed MRK with an annualized return of 4.15%, while MRK has yielded a comparatively higher 12.31% annualized return.

G

• 1D: -0.53%
• 1M: -5.76%
• YTD: -19.98%
• 6M: -10.31%
• 1Y: -24.83%
• 3Y*: -5.45%
• 5Y*: -1.58%
• 10Y*: 4.15%

MRK

• 1D: 1.85%
• 1M: -2.13%
• YTD: 15.13%
• 6M: 45.62%
• 1Y: 38.88%
• 3Y*: 7.42%
• 5Y*: 13.86%
• 10Y*: 12.31%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

G vs. MRK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

G

G Risk / Return Rank: 11
G Sharpe Ratio Rank: 12
G Sortino Ratio Rank: 14
G Omega Ratio Rank: 12
G Calmar Ratio Rank: 9
G Martin Ratio Rank: 7

MRK

MRK Risk / Return Rank: 79
MRK Sharpe Ratio Rank: 82
MRK Sortino Ratio Rank: 78
MRK Omega Ratio Rank: 76
MRK Calmar Ratio Rank: 80
MRK Martin Ratio Rank: 79

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

G vs. MRK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Genpact Limited (G) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	G	MRK	Difference
Sharpe ratio Return per unit of total volatility	-0.69	1.34	-2.04
Sortino ratio Return per unit of downside risk	-0.85	1.96	-2.81
Omega ratio Gain probability vs. loss probability	0.88	1.25	-0.37
Calmar ratio Return relative to maximum drawdown	-0.89	2.19	-3.08
Martin ratio Return relative to average drawdown	-1.62	5.34	-6.96
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

G vs. MRK - Sharpe Ratio Comparison

The current G Sharpe Ratio is -0.69, which is lower than the MRK Sharpe Ratio of 1.34. The chart below compares the historical Sharpe Ratios of G and MRK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	G	MRK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.69	1.34	-2.04
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.06	0.60	-0.66
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.15	0.54	-0.39
Sharpe Ratio (All Time) Calculated using the full available price history	0.18	0.49	-0.30

Correlation

The correlation between G and MRK is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

G vs. MRK - Dividend Comparison

G's dividend yield for the trailing twelve months is around 1.87%, less than MRK's 2.76% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
G Genpact Limited	1.87%	1.45%	1.42%	1.58%	1.08%	0.81%	0.94%	0.81%	1.11%	0.76%	0.00%	0.00%
MRK Merck & Co., Inc.	2.76%	3.12%	3.14%	2.72%	2.52%	3.41%	3.03%	2.48%	2.60%	3.36%	3.14%	3.43%

Drawdowns

G vs. MRK - Drawdown Comparison

The maximum G drawdown since its inception was -64.14%, smaller than the maximum MRK drawdown of -68.61%. Use the drawdown chart below to compare losses from any high point for G and MRK.

Drawdown Indicators

	G	MRK	Difference
Max Drawdown Largest peak-to-trough decline	-64.14%	-68.61%	+4.47%
Max Drawdown (1Y) Largest decline over 1 year	-27.35%	-15.67%	-11.68%
Max Drawdown (5Y) Largest decline over 5 years	-41.31%	-43.44%	+2.13%
Max Drawdown (10Y) Largest decline over 10 years	-49.47%	-43.44%	-6.03%
Current Drawdown Current decline from peak	-31.58%	-4.04%	-27.54%
Average Drawdown Average peak-to-trough decline	-15.29%	-18.89%	+3.60%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.95%	7.44%	+7.51%

Volatility

G vs. MRK - Volatility Comparison

Genpact Limited (G) has a higher volatility of 7.76% compared to Merck & Co., Inc. (MRK) at 5.85%. This indicates that G's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	G	MRK	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.76%	5.85%	+1.91%
Volatility (6M) Calculated over the trailing 6-month period	26.62%	19.79%	+6.83%
Volatility (1Y) Calculated over the trailing 1-year period	35.87%	29.08%	+6.79%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	27.88%	23.30%	+4.58%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.64%	22.68%	+4.96%

Financials

G vs. MRK - Profitability Comparison

The chart below illustrates the profitability comparison between Genpact Limited and Merck & Co., Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

G - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Genpact Limited reported a gross profit of 482.29M and revenue of 1.32B. Therefore, the gross margin over that period was 36.6%.

MRK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported a gross profit of 15.20B and revenue of 16.40B. Therefore, the gross margin over that period was 92.7%.

G - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Genpact Limited reported an operating income of 195.46M and revenue of 1.32B, resulting in an operating margin of 14.8%.

MRK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported an operating income of 8.74B and revenue of 16.40B, resulting in an operating margin of 53.3%.

G - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Genpact Limited reported a net income of 143.09M and revenue of 1.32B, resulting in a net margin of 10.9%.

MRK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported a net income of 2.96B and revenue of 16.40B, resulting in a net margin of 18.1%.